Search
Liana’s story begins nine years ago. It starts with a sore ankle, a fever, a trip to the emergency room and clinic and finally a diagnosis of acute rheumatic fever (ARF).
News & Events
Old, painful rheumatic heart disease treatment could be phased outAn international trial reveals 95% of rheumatic heart disease patients prefer less painful penicillin injections under the skin, aiming to improve treatment adherence.
News & Events
Unified response critical to address spread of ‘flesh eating’ bacteriaA surge in invasive group A streptococcal reports in Australia has prompted The Kids Research Institute Australia researchers to call for a unified national public health response, with cases tipped to increase.
Contact us If you'd like to get in touch, please contact Marie Nadal-Sims by phone or email. Phone: (08) 6319 1001 Email: IICPerth@thekids.org.au All
A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.
Research
Pneumococcal Conjugate Vaccines Are Protective Against Respiratory Syncytial Virus Hospitalizations in Infants: A Population-Based Observational StudyPneumococcal conjugate vaccines (PCV) reduced the risk of respiratory syncytial virus (RSV) in a randomized clinical trial. We aimed to assess the real-world effectiveness of PCV on RSV-hospitalizations among Western Australian infants.
Research
Biofilms and intracellular infection in otitis mediaOtitis media (OM), middle ear infection, represents a significant burden on children, their families, and the healthcare system. OM is the major cause of hearing loss in children and if left untreated in children who suffer chronic and recurrent forms of OM, this disease can have serious life-long sequelae.
Research
Microevolution and Its Impact on Hypervirulence, Antimicrobial Resistance, and Vaccine Escape in Neisseria meningitidisNeisseria meningitidis is commensal of the human pharynx and occasionally invades the host, causing the life-threatening illness invasive meningococcal disease. The meningococcus is a highly diverse and adaptable organism thanks to natural competence, a propensity for recombination, and a highly repetitive genome.
Research
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studiesThe meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) is licensed for use in children aged 10 years or older for protection against invasive serogroup B meningococcal disease. Because young children are at increased risk of invasive meningococcal disease, MenB-FHbp clinical data in this population are needed.
Research
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY VaccineA MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.